Very interesting news release  to share. This compound doe not kill
healthy cells according to the report.

Weston, Florida, January 14, 2006

Cytorex Biosciences, Inc. (Cytorex), a Florida based biotechnology
company, announced today the publication in the January 2006 issue of
the Journal of Carcinogenesis, of a research report related to in-vitro
efficacy testing in cancer cell lines and normal cell lines, with
Cytoreg®, their lead anti-cancer compound.

The title of the publication is: "Cytoreg® inhibits growth and
proliferation of human adenocarcinoma cells via induction of
apoptosis". The corresponding author is James Kumi-Diaka, DVM, PhD,
from Florida Atlantic University (FAU), and the co-authors of the
report are: Manzur Hassanhi, MD, PhD , professor of Immunology and
Cancer Research Scientist, from the University of Zulia (Venezuela),
Brown Jayaan(FAU), Kendra Merchant (FAU) , Carlos M Garcia (Cytorex),
and William Jimenez (Cytorex).

Abstract: "Cancer is one of the devastating neovascular diseases that
incapacitate so many people the world over. Recent reports from the
National Cancer Institute indicate some significant gain therapy and
cancer management as seen in the increase in the 5-year survival rate
over the past two decades. Although near-perfect cure rate have been
reported in the early-stage disease, these data reveal high recurrence
rate and serious side effects including second malignancies and
fatalities. Most of the currently used anticancer agents are only
effective against proliferating cancer cells. Thus attention has been
focused on potential anti-cancer agents capable of killing cancer cells
independent of the cell cycle state, to ensure effective elimination of
most cancer cells. The objective of this study was to test the
Chemosensitivity and potential mechanism of action of a novel cancer
drug, Cytoreg®, in a panel of human cancer cells. Methods: the study
was performed using a series of bioassays including Trypan blue
exclusion, MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal DNA
fragmentation Apoptosis Assay, and the Caspase protease CPP32 activity
assays. Results: Cytoreg® induced significant dose- and time-dependent
inhibition of growth in all the cells; with significant differences in
chemosensitivity (P 1:300). Cytoreg®-induced caspase protease-3
(CPP32) activation significantly and positively correlated with
apoptosis induction and growth inhibition; thus implicating CPP32 as
the principal death pathway in Cytoreg®-induced apoptosis. Conclusion:
Cytoreg® exerted a dose-and time-dependent growth inhibitory effect in
all the target cells through induction of apoptosis via the CPP32 death
pathway, independent of hormonal sensitivity of the cells. The present
data indicate that not only could CPP32 provide a potential target for
regulation of Cytoreg®-induced apoptosis but also that Cytoreg® could
play a significant role in chemotherapeutic regimen in many human
malignant tumors."

"This is the first of several research reports about Cytoreg® we
plan to submit, during 2006.  to peer-reviewed journals", said Dr.
James Kumi-Diaka, Professor of Biology of Cancer at Florida Atlantic
University in Davie, Florida.

"Cytoreg® has great potential as an anti-cancer compound, and
additional research has shown that this compound's toxicity level is
very low if compared with current approved chemotherapeutical
agents", indicated Dr. Manzur Hassanhi, Professor of Immunology and
Cancer Research Scientist of the University of Zulia
(Maracaibo-Venezuela).

Both Kumi-Diaka and Hasannhi, have lead since 2003 a multinational
research team involved in the discovery of Cytoreg® as an anti-cancer
agent.

According to Cytorex's Vice-President  & CFO, William Jimenez, who is
also a co-author of this research report, "Cytoreg® is a therapeutic
agent for cellular regulation, with antineoplastic properties which may
also be used to fight immunological diseases. Cytoreg® constitutes a
balanced mixture of strong and weak acids in an aqueous medium;
resembling a buffer without using salts. Cytoreg® is transferred into
a cellular system through ionic transport due to its low molecular
weight, where each ion acts concurrently in cells, turning Cytoreg®
into a highly efficient "smart-drug." Cytoreg®'s numerous
mechanisms of action are exerted through the cellular membrane".

A complete PDF version of the report is can be accessed through the
Journal of Carcinogenesis web page:


http://www.carcinogenesis.com/content/pdf/1477-3163-5-1.pdf